Patents

Case summaries and articles about  patents.

June 30, 2015

Writing Provisional Software Patent Applications

In the age of the “Lean Startup” $100,000 can be enough to get a startup well off the ground. However, with such tight budgets and limited funding there is often not much room left to pay a professional patent agent several thousand dollars to draft your patent application. This article provides some pointers on how to draft your own provisional software patent application.
June 30, 2015

ABQB Upholds Patent Assignment from Employee Despite Partially Unpaid Salary

Groves v Canasonics Inc, 2015 ABQB 314 - After a falling out between a director and Canasonics Inc., the former director sought to ensure that any intellectual property in critical unpatented tools remained his own, and sought to reverse the transfer of a number of patents that he had already assigned to the company.
June 27, 2015

Patent on Airport Security Trays Proven to have a Surprising Impact on Airport Efficiency

CD 1377 - Security Point Media's patent on “Advertising Trays for Security Screening” was found to be nonobvious considering a number of factors, such as the impact of the invention on the industry.
May 21, 2015

FCA Upholds Gilead Product Specificity Requirement

ViiV Healthcare ULC v Teva Canada Limited, 2015 FCA 93 - The FCA confirmed that paragraph 4(2)(a) of the Patented Medicines (Notice of Compliance Regulations) requires that a patent listed on the register requires an “exacting threshold of specificity” between what is claimed in the patent and what has been approved in the Notice of Compliance. However, proposed amendments to the PM(NOC) Regulations would reverse this holding.
May 20, 2015

PM(NOC) Amendments to Reverse Gilead and Viiv Decisions Regarding Product Specificity Requirement for Combination Drugs

The proposed amendments would dispose of the product specificity requirement that was interpreted by the Federal Court of Appeal in paragraphs 4(2)(a) and 4(2)(b) of the PM(NOC) Regulations.
May 18, 2015

Hydrogen Economy Patent Rejected for Ambiguity

Commissioner’s Decision #1376 - The Application, which sought to patent what is essentially one manifestation of the hydrogen economy, was rejected for ambiguity since the Application’s use of the term “water… inputs” as claimed was not supported by the description. Water is only ever described as taking part in intermediary steps in the claimed method, not as an energy input, as in hydroelectric power.
May 12, 2015

The Oft Missed Synergy: Patents and SRED

Flat-out ignoring patents and SRED can result in leaving a lot of value on the table. Whatever one may think of patents, it is a fact that they can provide enormous value to a technology company if they are done correctly. By the same token, a successful SRED claim can lead to a significant short term financial boost for cash conscious companies.
April 30, 2015

Google Offers to Purchase your Patents

From May 8, 2015 through May 22, 2015, Google will be accepting applications from patent-holders wishing to sell any patent to Google through its experimental Patent Purchase Program. Google hopes that its program will improve the marketplace for patents for everyone, but especially for smaller participants, who too often end up selling their patents to patent trolls.
April 22, 2015

Determining the Common General Knowledge from the Background of a Patent Upheld as a Reasonable Factual Finding

Newco Tank Corp v Canada (Attorney General) 2015 FCA 47 - The Board made a reasonable factual finding when it found that the background knowledge of the person skilled in the art was described in the background information of a patent. This determination was instrumental in the Board’s determination that the patent was obvious.
March 24, 2015

Mylan-Tadalafil does not Infringe Eli Lilly’s Formulation Patent in NOC Proceeding

Eli Lilly Inc v Mylan Pharmaceuticals ULC, 2015 FC 178 - Mylan did not infringe the ‘948 Patent because the Mylan’s tadalafil compound did not have the claimed particle size distribution and the formulation did not contain the claimed concentration of hydrophilic binder. The Court rejected two purposive arguments by Eli Lilly in favour of a more literal reading of the patent.